The University of Michigan is a national leader in basic, translational, and clinical research
on pediatric brain tumors.
Not exact matches
The Kamens claim the main thing that distinguishes their foundation from other
brain tumor foundations is their focus
on pediatric brain cancer specifically, as well as their close ties with pharmaceutical and biotech companies working in the fields of immunotherapy and target gene therapy.
He has also authored several chapters in scholarly texts
on subjects ranging from
pediatric concussion to
brain tumors in children.
He remains a leader in supportive care and research in
pediatric oncology, with a special focus
on neuroblastoma, non-Hodgkin lymphoma, Ewing Sarcoma, acute lymphoblastic leukemia and
brain tumors.
The six
tumors with matched normal DNA harbored 15 somatic mutations
on average (range 3 - 31), a mutation rate lower than adult GBM but higher than another
pediatric brain tumor, medulloblastoma.
Our groundbreaking
Pediatric Mi - Oncoseq Program is an internationally known precision oncology program focusing
on the genetic analysis of
pediatric cancer patients including in children with malignant
brain tumors, and determines whether targeted treatments may be available based upon their personalized
tumor genomic sequencing profiles.
Dr. Biegel's primary research interests are focused
on the genetics of
pediatric rhabdoid
tumors and childhood
brain tumors.